Intravenous anesthetics inhibit human paraoxonase-1 (PON1) activity in vitro and in vivo

被引:52
作者
Alici, Haci Ahmed [2 ]
Ekinci, Deniz [1 ]
Beydemir, Suekrue [1 ]
机构
[1] Ataturk Univ, Fac Arts & Sci, Dept Chem, Div Biochem, TR-25240 Erzurum, Turkey
[2] Ataturk Univ, Fac Med, Dept Anesthesiol & Intens Care, TR-25240 Erzurum, Turkey
关键词
Paraoxonase; Inhibition; Anesthetic drugs;
D O I
10.1016/j.clinbiochem.2008.06.017
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 [基础医学];
摘要
Objectives: Here we evaluated the in vitro and in vivo effects of the intravenous anesthetics, etomidate, propofol, and ketamine, on the activity of human serum paraoxonase (hPON1). Design and methods: hPON1 was purified from human serum using simple chromatographic methods, including DEAE-Sephadex anion exchange and Sephadex G-200 gel filtration chromatography. Results: The three anesthetics dose-dependently decreased in vitro hPON1 activity. Inhibition mechanisms are: etomidate was noncompetitive, propofol was competitive, and ketamine was uncompetitive. In vivo studies were performed on five patients for each drug. PON1 was significantly inhibited by 0.3 mg/kg etomidate (p < 0.05), 2 mg/kg propofol (p < 0.001), and 1 mg/kg ketamine (p < 0.05) for up to 5 min following intravenous administration. Conclusions: Our results showed that anesthetics significantly inhibit hPON1 activity both in vitro and in vivo, with rank order etomidate > propofol > ketamine in vitro, and propofol > etomidate > ketamine in vivo. (c) 2008 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1384 / 1390
页数:7
相关论文
共 64 条
[1]
SERUM PARAOXONASE ACTIVITY, CONCENTRATION, AND PHENOTYPE DISTRIBUTION IN DIABETES-MELLITUS AND ITS RELATIONSHIP TO SERUM-LIPIDS AND LIPOPROTEINS [J].
ABBOTT, CA ;
MACKNESS, MI ;
KUMAR, S ;
BOULTON, AJ ;
DURRINGTON, PN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (11) :1812-1818
[2]
The 'evolvability' of promiscuous protein functions [J].
Aharoni, A ;
Gaidukov, L ;
Khersonsky, O ;
Gould, SM ;
Roodveldt, C ;
Tawfik, DS .
NATURE GENETICS, 2005, 37 (01) :73-76
[3]
Human serum paraoxonase (PON1) activity in acute organophosphorous insecticide poisoning [J].
Akgür, SA ;
Öztürk, P ;
Solak, I ;
Moral, AR ;
Ege, B .
FORENSIC SCIENCE INTERNATIONAL, 2003, 133 (1-2) :136-140
[4]
[Anonymous], IRN J MED SCI
[5]
Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: A mathematically based toxicokinetic model [J].
Ashani, Y ;
Pistinner, S .
TOXICOLOGICAL SCIENCES, 2004, 77 (02) :358-367
[6]
Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration [J].
Baskol, G ;
Karakucuk, S ;
Oner, AO ;
Baskol, M ;
Kocer, D ;
Mirza, E ;
Saraymen, R ;
Üstdal, M .
OPHTHALMOLOGICA, 2006, 220 (01) :12-16
[7]
Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis [J].
Baskol, G ;
Demir, H ;
Baskol, M ;
Kilic, E ;
Ates, F ;
Kocer, D ;
Muhtaroglu, S .
CLINICAL BIOCHEMISTRY, 2005, 38 (10) :951-955
[8]
Beydemir S, 2003, POL J PHARMACOL, V55, P787
[9]
Billeclke S, 2000, DRUG METAB DISPOS, V28, P1335
[10]
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3